Download PDF
Am J Perinatol 2023; 40(12): 1345-1350
DOI: 10.1055/a-1585-6093
Original Article

Fluid Intake in the First Week of Life and the Duration of Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants

Hussnain Mirza
1   Center for Neonatal Care, University Central Florida College of Medicine, Advent Health for Children, Orlando, Florida
,
Jorge Garcia
2   Division of Pediatric Cardiology, Advent Health for Children, Orlando, Florida
,
Chelsea Bell
3   Clinical Nutrition Program, Advent Health for Children, Orlando, Florida
,
Kristen Jones
4   Pediatric Pharmacy Services, Advent Health for Children, Orlando, Florida
,
Vicki Flynn
5   Office of Pediatric Research Advancement and Support, Advent Health, Orlando, Florida
,
Julie Pepe
5   Office of Pediatric Research Advancement and Support, Advent Health, Orlando, Florida
,
William Oh
5   Office of Pediatric Research Advancement and Support, Advent Health, Orlando, Florida
› Author Affiliations Funding This study was supported by our internal funding provided by Advent Health for Children, Orlando, FL.
› Further Information
    Permissions and Reprints

Abstract

Objective This study aimed to determine the association between daily fluid intake and the duration of hemodynamically significant patent ductus arteriosus (hsPDA).

Study Design This is a retrospective cohort study of extremely preterm infants (<29 weeks) admitted in the Neonatal Intensive Care Unit of the Advent Health for Children from January 2013 to March 2016, if hsPDA was diagnosed in first week of life and serial echocardiograms were available. Diagnosis of hsPDA was based on a scoring system and its duration was estimated from serial echocardiograms. Cohort was divided into two groups based on duration of hsPDA (<1week, group A and ≥1 week, group B). Daily fluid intake was categorized as prescribed and actual. Prescribed volume was ordered by clinicians based on birth weight, not including trophic feeds, intravenous (IV) boluses or transfusions, etc. Actual intake was calculated by the electronic medical records based on daily weights and included all enteral or parenteral fluids. Multivariate analysis was performed to determine an association between total daily fluid intake over the first week of life and the duration of hsPDA. Two groups were compared to observe the difference between prescribed and actual daily fluid intakes.

Results We enrolled 50 infants in group A and 76 in group B. Infants in group B were of significantly lower gestation and required prolonged ventilation and hospitalization. An association between higher fluid intake in the first 2 days of life and prolonged duration of hsPDA was confirmed by multivariate analysis. Actual fluid intake was significantly higher than prescribed total fluid intake in first 4 days of life for infants in both groups.

Conclusion In extremely preterm infants, higher fluid intake in first 2 days of life is associated with prolonged duration of hsPDA. Actual daily fluid intake can be significantly higher than prescribed daily fluids due to daily weight changes and additional fluid administration.

Key Points

  • In preterm infants, actual daily fluid intake may be higher than prescribed volume.

  • Higher daily fluid intake in first week of life is associated with prolonged duration of PDA.

  • PDA scoring system can be helpful for objective assessment of PDA in preterm infants.

Keywords

PDA - extremely preterm infants - total daily fluid intake


Publication History

Received: 08 August 2021

Accepted: 09 August 2021

Accepted Manuscript online:
12 August 2021

Article published online:
23 November 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Rolland A, Shankar-Aguilera S, Diomandé D, Zupan-Simunek V, Boileau P. Natural evolution of patent ductus arteriosus in the extremely preterm infant. Arch Dis Child Fetal Neonatal Ed 2015; 100 (01) F55-F58
    CrossrefPubMedGoogle Scholar
  • 2 Heuchan AM, Clyman RI. Managing the patent ductus arteriosus: current treatment options. Arch Dis Child Fetal Neonatal Ed 2014; 99 (05) F431-F436
    CrossrefPubMedGoogle Scholar
  • 3 Hermes-DeSantis ER, Clyman RI. Patent ductus arteriosus: pathophysiology and management. J Perinatol 2006; 26 (Suppl. 01) S14-S18 , discussion S22–S23
    CrossrefPubMedGoogle Scholar
  • 4 Tsui I, Ebani E, Rosenberg JB, Lin J, Angert RM, Mian U. Patent ductus arteriosus and indomethacin treatment as independent risk factors for plus disease in retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 2013; 50 (02) 88-92
    CrossrefPubMedGoogle Scholar
  • 5 Mirea L, Sankaran K, Seshia M. et al; Canadian Neonatal Network. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias. J Pediatr 2012; 161 (04) 689-94.e1 , e681
    CrossrefPubMedGoogle Scholar
  • 6 Madan JC, Kendrick D, Hagadorn JI, Frantz III ID. National Institute of Child Health and Human Development Neonatal Research Network. Patent ductus arteriosus therapy: impact on neonatal and 18-month outcome. Pediatrics 2009; 123 (02) 674-681
    CrossrefPubMedGoogle Scholar
  • 7 Clyman R, Cassady G, Kirklin JK, Collins M, Philips III JB. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Pediatr 2009; 154 (06) 873-876
    CrossrefPubMedGoogle Scholar
  • 8 Abdel-Hady H, Nasef N, Shabaan AE, Nour I. Patent ductus arteriosus in preterm infants: do we have the right answers?. BioMed Res Int 2013; 2013: 676192
    CrossrefPubMedGoogle Scholar
  • 9 Letshwiti JB, Semberova J, Pichova K, Dempsey EM, Franklin OM, Miletin J. A conservative treatment of patent ductus arteriosus in very low birth weight infants. Early Hum Dev 2017; 104: 45-49
    CrossrefPubMedGoogle Scholar
  • 10 Ezenwa B, Pena E, Schlegel A, Bapat R, Shepherd EG, Nelin LD. Effects of practice change on outcomes of extremely preterm infants with patent ductus arteriosus. Acta Paediatr 2019; 108 (01) 88-93
    CrossrefPubMedGoogle Scholar
  • 11 Wyllie JP, Gupta S. Prophylactic and early targeted treatment of patent ductus arteriosus. Semin Fetal Neonatal Med 2018; 23 (04) 250-254
    CrossrefPubMedGoogle Scholar
  • 12 Lee JA. Practice for preterm patent ductus arteriosus; focusing on the hemodynamic significance and the impact on the neonatal outcomes. Korean J Pediatr 2019; 62 (07) 245-251
    CrossrefPubMedGoogle Scholar
  • 13 Sehgal A, Paul E, Menahem S. Functional echocardiography in staging for ductal disease severity: role in predicting outcomes. Eur J Pediatr 2013; 172 (02) 179-184
    CrossrefPubMedGoogle Scholar
  • 14 Mirza H, Garcia J, McKinley G. et al. Duration of significant patent ductus arteriosus and bronchopulmonary dysplasia in extremely preterm infants. J Perinatol 2019; 39 (12) 1648-1655
    CrossrefPubMedGoogle Scholar
  • 15 Warburton D, Bell EF, Stonestreet BS, Oh W. Echocardiographic effects of high and low volumes of maintenance fluid administration in low-birth-weight infants. Dev Pharmacol Ther 1983; 6 (01) 45-54
    CrossrefPubMedGoogle Scholar
  • 16 Bell EF, Oh W. Water requirement of premature newborn infants. Acta Paediatr Scand Suppl 1983; 305: 21-26
    CrossrefPubMedGoogle Scholar
  • 17 Bell EF, Warburton D, Stonestreet BS, Oh W. Effect of fluid administration on the development of symptomatic patent ductus arteriosus and congestive heart failure in premature infants. N Engl J Med 1980; 302 (11) 598-604
    CrossrefPubMedGoogle Scholar
  • 18 Abbas S, Keir AK. In preterm infants, does fluid restriction, as opposed to liberal fluid prescription, reduce the risk of important morbidities and mortality?. J Paediatr Child Health 2019; 55 (07) 860-866
    CrossrefPubMedGoogle Scholar
  • 19 Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2014; (12) CD000503
    PubMedGoogle Scholar
  • 20 Oh W, Poindexter BB, Perritt R. et al; Neonatal Research Network. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr 2005; 147 (06) 786-790
    CrossrefPubMedGoogle Scholar
  • 21 Agnoli GC, Borgatti R, Cacciari M, Lenzi P, Marinelli M, Stipo L. Renal synthesis of prostacyclin and thromboxane in healthy women: differential effects of a short-term saline loading. Prostaglandins Leukot Essent Fatty Acids 2000; 62 (02) 111-117
    CrossrefPubMedGoogle Scholar
  • 22 Tan SY, Sandwisch DW, Mulrow PJ. Sodium intake as a determinant of urinary prostaglandin E2 excretion. Prostaglandins Med 1980; 4 (01) 53-63
    CrossrefPubMedGoogle Scholar
  • 23 Reller MD, Lorenz JM, Kotagal UR, Meyer RA, Kaplan S. Hemodynamically significant PDA: an echocardiographic and clinical assessment of incidence, natural history, and outcome in very low birth weight infants maintained in negative fluid balance. Pediatr Cardiol 1985; 6 (01) 17-23
    CrossrefPubMedGoogle Scholar
  • 24 Verma RP, Shibli S, Fang H, Komaroff E. Clinical determinants and utility of early postnatal maximum weight loss in fluid management of extremely low birth weight infants. Early Hum Dev 2009; 85 (01) 59-64
    CrossrefPubMedGoogle Scholar
  • 25 Warnock A, Szatkowski L, Lakshmanan A, Lee L, Kelsall W. Surgical management of patent ductus arteriosus in pre-term infants - a british paediatric surveillance study. BMC Pediatr 2021; 21 (01) 270
    CrossrefPubMedGoogle Scholar